MRD-Guided Elranatamab Maintenance Therapy
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 65 patients (estimated)
- Sponsors
- Washington University School of Medicine
- Collaborators
- Pfizer, National Comprehensive Cancer Network, Rapid Novor
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3, Maintenance, Post-Autologous Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1969
- NCT Identifier
- NCT06483100
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.